A Phase I Clinical Trial of AZD1775 in Combination With Neoadjuvant Weekly Docetaxel and Cisplatin Before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.

CONCLUSIONS: The triplet combination of AZD1775, cisplatin and docetaxel is safe and tolerable. Preliminary results show promising anti-tumor efficacy in advanced HNSCC, meriting further investigation at the recommended phase 2 dose. PMID: 29535125 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29535125?dopt=Abstract

Source: Clinical Cancer Research - March 13, 2018 Category: Cancer & Oncology Authors: Méndez E, Rodriguez CP, Kao M, Raju SC, Diab A, Harbison RA, Konnick EQ, Mugundu G, Santana-Davila R, Martins R, Futran ND, Chow LQM Tags: Clin Cancer Res Source Type: research